CANF

CANF

USD

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

$1.130-0.035 (-3.038%)

السعر في الوقت الحقيقي

Healthcare
التكنولوجيا الحيوية
إسرائيل

مخطط الأسعار

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$1.165

الأعلى

$1.170

الأدنى

$1.130

الحجم

0.01M

أساسيات الشركة

القيمة السوقية

15.8M

الصناعة

التكنولوجيا الحيوية

البلد

Israel

إحصاءات التداول

متوسط الحجم

0.29M

البورصة

ASE

العملة

USD

نطاق 52 أسبوعاً

الأدنى $1.13الحالي $1.130الأعلى $4.69

أخبار ذات صلة

GlobeNewswire

Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients

Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

عرض المزيد
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Analyst Upgrades

D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target

D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.

عرض المزيد
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
GlobeNewswire

Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

عرض المزيد
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
GlobeNewswire

Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships

Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory

عرض المزيد
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
GlobeNewswire

Can-Fite Reports 2024 Financial Results and Clinical Update

RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and

عرض المزيد
Can-Fite Reports 2024 Financial Results and Clinical Update

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.